Skip to Main Content

Telehealth company Ro has reached an agreement with the National Institute on Aging to create a registry of patients that could participate in Alzheimer’s disease research, a new approach to tackle the stubborn issue of recruitment for clinical trials.

Ro, which is best known for prescribing hair loss and erectile dysfunction medication online, will use its platform to recruit and screen patients who may be at risk of Alzheimer’s or dementia. The hope is that Ro’s consumer-friendly technology platform and broad user base will streamline the process of finding more patients, helping overcome what NIA senior investigator Madhav Thambisetty calls “one of the major bottlenecks” in Alzheimer’s research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment